In this study, we hypothesized that polymorphisms of the PD-L1 gene may alter the immune checkpoint function, thereby influencing clinical outcomes of response to immune checkpoint inhibitors in patients with lung cancer. The gene discussed is CD274; the disease is lung carcinoma.